ELITech generates most of its revenues in Europe, with significant business also in North and Latin America. Its major R&D and operations sites are in Italy, the United States, France and Germany.

ELITech generates most of its revenues in Europe, with significant business also in North and Latin America. Its major R&D and operations sites are in Italy, the United States, France and Germany.

ELITechGroup Molecular Diagnostics Receives FDA Clearance for its Real-Time PCR Assay for the Detection of Herpes Simplex Virus 1&2 and ELITe InGenius® Sample-to-Result Instrument October 31 ...

ELITechGroup, known for its innovative molecular diagnostic (MDx) systems InGenius® and BeGenius®, has over 500 employees and holds more than 40 active patents.

ELITech offers the proprietary, fully automated sample-to-answer (S2A) systems InGenius® and BeGenius® for molecular testing in mid-sized hospitals Diversified ELITech MDx assay portfolio ...

Mirina, the new entity, gained Nanogen’s technology that aims to enhance miRNA drugs. Nanogen and The Elitech Group entered a definitive merger agreement. Separately, Nanogen also created a ...

Bruker Corporation announced today that it has entered into a definitive share purchase agreement with TecFin S. à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm ...

ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical ...